An academic neurology department conducts a prospective cohort study to evaluate a novel disease-modifying therapy for patients with secondary progressive multiple sclerosis. The primary outcome is the time to first documented persistent disability progression. Initial unadjusted survival analysis comparing the novel therapy to the institutional standard of care yields a hazard ratio (HR) of 0.72 (95% CI: 0.48 - 1.08, p = 0.11).
Subsequently, the investigators perform a pre-specified multivariate Cox proportional hazards regression, adjusting for patient age at diagnosis, baseline Expanded Disability Status Scale (EDSS) score, and T2 lesion volume on initial MRI. This adjusted analysis demonstrates an HR of 0.61 (95% CI: 0.41 - 0.90, p = 0.01).
Based on these statistical findings, which of the following is the most accurate conclusion regarding the study results?
- The unadjusted analysis fails to demonstrate a statistically significant delay in disability progression, but covariate adjustment reveals a significant protective effect.Answer
- BThe unadjusted p-value indicates an 11% probability that the novel therapy has no effect on disability progression, which decreases to 1% after adjustment.
- CThe significant shift in the hazard ratio upon adjustment confirms that baseline EDSS score and MRI lesion volume are effect modifiers.
- DBecause the unadjusted 95% confidence interval includes 1.0, the novel therapy and standard care are proven to be statistically equivalent.
- EThe adjusted analysis is invalid because multivariate regression is only appropriate when the unadjusted bivariate analysis achieves a p-value of less than 0.05.